Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)
慢性粒细胞白血病酪氨酸激酶抑制剂停药后，罗培干扰素α-2b与监测的随机3期试验（ENDURE/CML-IX）
期刊:Leukemia
影响因子:13.4
doi:10.1038/s41375-025-02859-1
Burchert, Andreas; Nicolini, Franck E; le Coutre, Philipp; Saussele, Susanne; Hochhaus, Andreas; Tuere, Evin; Metzelder, Stephan K; Pauck, Kim; Garn, Holger; Raifer, Hartmann; Huber, Magdalena; Gattermann, Norbert; Crysandt, Martina; Schafhausen, Philippe; Bormann, Matthias; Radsak, Markus P; Guerci-Bresler, Agnès; Illmer, Thomas; Goebeler, Maria E; Herhaus, Peter; Teichmann, Lino L; Franke, Georg-Nikolaus; Lang, Fabian; Krause, Stefan W; Möhle, Robert; Klausmann, Martine; Stegelmann, Frank; Lutz, Christoph; Etienne, Gabriel; Stoltefuß, Andrea; Göthert, Joachim R; Ernst, Thomas; Abu-Samra, Maisun; Höffkes, Heinz-Gert; Neubauer, Andreas; Wang, Ying; Weiland, Paul; Otto, Clara; Kiessler, Lea; Weber, Theresa; Kroning, Lea; Nist, Andrea; Stiewe, Thorsten; Hehlmann, Rüdiger; Aminossadati, Behnaz; Wittenberg, Michael; Winterstein, Kerstin; Oellerich, Thomas; Lechner, Marcus; Pfirrmann, Markus; Schade-Brittinger, Carmen; Klemm, Paul; Michel, Christian
